Oregon Therapeutics & Lantern Pharma Launch Strategic AI Collaboration to Optimize Development of First-In-Class Drug Candidate XCE853 – A Potent Inhibitor of Cancer Metabolism : vimarsana.com

Oregon Therapeutics & Lantern Pharma Launch Strategic AI Collaboration to Optimize Development of First-In-Class Drug Candidate XCE853 – A Potent Inhibitor of Cancer Metabolism

XCE853 is Oregon Therapeutic’s first-in-class, and potentially best-in-class PDI inhibitor, exhibiting potent preclinical efficacy across multiple solid and hematological cancers, and is ready to...

Related Keywords

Oregon , United States , France , French , Shili Xu , Nouri Neamati , Saranya Sankar , Securities Exchange , Lantern Pharma Inc , Sandrine Court , Linkedin , Exchange Commission On , Nasdaq , Lantern Pharma , Oregon Therapeutics , Panna Sharma , Drug Discovery Today , Koreanj Intern Med , Cancer Journal , Molecular Biology , Starlight Therapeutics , Oregon Therapeutic , Clinical Phase , Securities Act , Securities Exchange Act , Risk Factors , Annual Report , Exchange Commission , Markets ,